Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art
The article is devoted to modern ideas about the role of drug interactions as a factor affecting the efficacy and safety of the use of direct oral anticoagulants (DOACs) in clinical practice. Data on drug interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in pat...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2022-07-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2756 |
| _version_ | 1826949515717902336 |
|---|---|
| author | S. R. Gilyarevsky |
| author_facet | S. R. Gilyarevsky |
| author_sort | S. R. Gilyarevsky |
| collection | DOAJ |
| description | The article is devoted to modern ideas about the role of drug interactions as a factor affecting the efficacy and safety of the use of direct oral anticoagulants (DOACs) in clinical practice. Data on drug interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients with cardiovascular diseases are given. Drug interactions for DOACs, depending on concomitant use of drugs that are inhibitors or inducers of the CYP3A4 enzyme or P-glycoprotein enzymes, are determined by most of the drug interactions of DOACs are considered. The results of studies in which drug interactions of DOACs were assessed by changes in indicators such as the area under the concentration-time curve and the maximum or minimum concentration of drugs in the blood are discussed. The data presented in the article may be useful for accounting for drug interactions in the treatment of patients with DOACs in clinical practice, despite the current lack of reasonable dose adjustment rules depending on the majority of such interactions. The data presented in the article suggest that apixaban has the fewest number of clinically significant interactions among the DOACs available in Russia. |
| first_indexed | 2024-03-08T14:00:03Z |
| format | Article |
| id | doaj.art-5f9bf596ac4744b783eb48d1259d0731 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:14:32Z |
| publishDate | 2022-07-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-5f9bf596ac4744b783eb48d1259d07312024-12-04T11:48:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532022-07-0118333234110.20996/1819-6446-2022-05-022034Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the ArtS. R. Gilyarevsky0Russian Medical Academy of Continuous Professional EducationThe article is devoted to modern ideas about the role of drug interactions as a factor affecting the efficacy and safety of the use of direct oral anticoagulants (DOACs) in clinical practice. Data on drug interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients with cardiovascular diseases are given. Drug interactions for DOACs, depending on concomitant use of drugs that are inhibitors or inducers of the CYP3A4 enzyme or P-glycoprotein enzymes, are determined by most of the drug interactions of DOACs are considered. The results of studies in which drug interactions of DOACs were assessed by changes in indicators such as the area under the concentration-time curve and the maximum or minimum concentration of drugs in the blood are discussed. The data presented in the article may be useful for accounting for drug interactions in the treatment of patients with DOACs in clinical practice, despite the current lack of reasonable dose adjustment rules depending on the majority of such interactions. The data presented in the article suggest that apixaban has the fewest number of clinically significant interactions among the DOACs available in Russia.https://www.rpcardio.online/jour/article/view/2756drug interactionsdirect oral anticoagulantsapixabanrivaroxabandabigatran |
| spellingShingle | S. R. Gilyarevsky Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art Рациональная фармакотерапия в кардиологии drug interactions direct oral anticoagulants apixaban rivaroxaban dabigatran |
| title | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art |
| title_full | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art |
| title_fullStr | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art |
| title_full_unstemmed | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art |
| title_short | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art |
| title_sort | clinically significant drug interactions for direct oral anticoagulants state of the art |
| topic | drug interactions direct oral anticoagulants apixaban rivaroxaban dabigatran |
| url | https://www.rpcardio.online/jour/article/view/2756 |
| work_keys_str_mv | AT srgilyarevsky clinicallysignificantdruginteractionsfordirectoralanticoagulantsstateoftheart |